-

 As stated in the report of Credit Suisse, the third quarterly revenue of SH PHARMA (02607.HK)  +0.080 (+0.414%)    Short selling $643.69K; Ratio 4.148%   shot up 27.7% to RMB 24.703 billion. Excluding special items, the increasing rate of earnings recorded a year-on-year increase of 13.9%, an acceleration from 5.8% in the first half of the year. It is believed that the annual core earnings will record a double-digit growth. The target price of Shanghai Pharmaceuticals was lifted from $15.04 to $19, which represents 15x of P/E. The rating was maintained at Neutral.
 

Comments

Post a Comment

Popular posts from this blog

-
Image
China VAST Industrial Urban Development Company Limited (06166.HK) - Summary    Summary       Company Info       IPO Info       Industry Comp       Financial Comp       Related News       Profit & Loss       Cash Flow       Balance Sheet     China VAST Industrial Urban Development Company Limited IPO Timetable Application Period 2014/08/13 - 2014/08/18  Fixed Date 2014/08/18  Announcement Date 2014/08/22  Refund Date 2014/08/22  Listing Date 2014/08/25  Basic Company Information Listing Market The Stock Exchange of Hong Kong (Main Board)  Industry Property Development  Background Others Major Business Area The PRC  Website http://www.vastiud.com   IPO Info Lot Size 1000  O...
Read more
-
UCD (01599) plans to raise Rmb600m from A shares issue    Beijing Urban Construction Design & Development Group (UCD) (01599) said it proposes to apply for initial public offering of Renminbi ordinary shares and listing.   The number of public issuance of shares amounts to not more than 149.86 million shares. The issuance price of A shares shall not be lower than Rmb2.91 per share.   The total proceeds raised from the issuance of A shares amount to Rmb600 million, which will be used for upgrading and reconstructing project of the design centre, the national  engineering...
Read more
-
PRADA Deutsche Bank believed and hoped PRADA (01913.HK)    -0.150 (-0.312%)    Short selling $12.87M; Ratio 35.577%   's performance had reached bottom in the third quarter. Looking ahead for the fourth quarter, with the Asian business getting back to normal, relatively low base in the second half of the year and the launch of new products, the company's sales growth may accelerate. Given the expected negative trend of the company's revenue, coupled with deleveraging, the company's EPS forecasts for FY2014-2015 were further cut by 7% and 5% respectively. The Hold rating was maintained and target price was reduced from $55 to $54. 
Read more